University of Washington study pays gamblers using GLP-1 drugs for data
The Addictions, Drug & Alcohol Institute is recruiting bettors on Ozempic, Wegovy or Rybelsus to examine whether the weight-loss medications affect gambling urges.

Researchers at the University of Washington are recruiting gamblers who take GLP-1 medications such as Ozempic, Wegovy or Rybelsus for a new academic study examining how the drugs affect betting behaviour.
The Addictions, Drug & Alcohol Institute (ADAI) at the university has launched the project, called the GAME Study — GLP-1s: Assessment of Gambling Motivations & Engagement Study — according to Casino.org News.
Prospective participants must complete a brief online questionnaire. Those selected then join a Zoom call with a member of the study team to show identification and a GLP-1 prescription or medication label on camera, Casino.org reported.
Participants are then asked to complete a 30-minute survey covering gambling urges, thoughts and behaviours both before and after they started taking a GLP-1. Anyone who finishes all three steps receives a $50 gift card, per the outlet's report.
Dr Ty Lostutter, an associate professor at UW Psychiatry & Behavioral Sciences, said problem gambling is a growing public health concern linked to the spread of legalised sports betting.
"There has been growing interest in the potential effects of these medications on addictive behaviors, but we still have much to learn about their relationship to gambling," Lostutter said, according to Casino.org. "We hope this study will help us better understand the experiences of individuals who gamble and are taking these medications, including whether they have noticed any changes in their gambling urges or behaviors."
Lostutter said qualifying participants will have experienced some form of gambling-related harm, whether currently or in the past, before starting a GLP-1. The study's enrollment website states that participants' identifying information will be kept separate from study data and limited to certain members of the study team or auditing agencies, Casino.org reported.
The GAME Study is funded by an ADAI Small Grant, according to the outlet.
The project follows other early academic work on a possible link between GLP-1 drugs and reduced gambling urges. Researchers at the University of Pennsylvania's Wharton School, including neuroscientist Michael Platt, have suggested the medications can dampen the brain's reward signals, reducing cravings for behaviours the brain desires. Platt has said long-term GLP-1 use can lead to "some structural remodeling of the brain" that may influence financial decision-making and reduce appetite for high-risk activity, Casino.org reported.
Boston University has published separate early research pointing to a similar effect. Dr Ivania Rizo, an assistant professor of medicine at Boston University and director of obesity medicine at Boston Medical Center, said the drugs act on brain regions such as the mesolimbic system that govern pleasure and motivation. "This system plays a role in cravings for food, but also for other rewarding behaviors like drinking alcohol, gambling, or even shopping," Rizo said, according to Casino.org.
Gallup reported in September that roughly 11% of the US adult population, or about 29 million people, is currently taking a GLP-1 medication, the outlet noted.